DGAP-Adhoc: Xlife Sciences AG: Active pharmaceutical ingredient for pneumonia caused by COVID-19 (coronavirus)
DGAP-Ad-hoc: Xlife Sciences AG / Key word(s): Miscellaneous Xlife Sciences AG: Active pharmaceutical ingredient for pneumonia caused by COVID-19 (coronavirus) About Xlife Sciences AG Xlife Sciences AG (m:access: XLS) is a Swiss company with focus on investing in promising technologies in the life science industry. Xlife Sciences AG is building the bridge from research and development to healthcare markets. Together with industrial partners or universities, Xlife Sciences AG leads projects through the proof-of-concept phase after an invention disclosure or start-up. Subsequently, the firm focuses on out-licensing or selling the company, often with a combination of a strategic partnership. Xlife Sciences AG offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage.
11-March-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | Xlife Sciences AG |
Klausstrasse 19 | |
8008 Zürich | |
Switzerland | |
Phone: | 0041 44 385 84 60 |
E-mail: | [email protected] |
Internet: | www.xlifesciences.ch |
ISIN: | CH0461929603 |
WKN: | A2PK6Z |
Listed: | Regulated Unofficial Market in Munich |
EQS News ID: | 993771 |
End of Announcement | DGAP News Service |
|
993771 11-March-2020 CET/CEST